1. Home
  2. VTSI vs LUNG Comparison

VTSI vs LUNG Comparison

Compare VTSI & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VirTra Inc.

VTSI

VirTra Inc.

HOLD

Current Price

$3.20

Market Cap

51.0M

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.39

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VTSI
LUNG
Founded
1993
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Miscellaneous manufacturing industries
Industrial Specialties
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
51.0M
57.9M
IPO Year
1999
2020

Fundamental Metrics

Financial Performance
Metric
VTSI
LUNG
Price
$3.20
$1.39
Analyst Decision
Strong Buy
Buy
Analyst Count
1
7
Target Price
$5.00
$5.38
AVG Volume (30 Days)
52.3K
349.1K
Earning Date
05-11-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
$185,971.00
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
$27.30
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.01
52 Week Low
$3.16
$1.13
52 Week High
$7.47
$3.88

Technical Indicators

Market Signals
Indicator
VTSI
LUNG
Relative Strength Index (RSI) 32.67 47.30
Support Level N/A $1.20
Resistance Level $3.60 $1.45
Average True Range (ATR) 0.16 0.11
MACD 0.01 -0.02
Stochastic Oscillator 3.48 33.33

Price Performance

Historical Comparison
VTSI
LUNG

About VTSI VirTra Inc.

VirTra Inc is a U.S.-based company that is engaged in the sale and development of judgmental use-of-force training simulators and firearms training simulators for law enforcement, military, and commercial uses. It sells simulators and related products across the globe through a direct sales force and international distribution partners. The services provided by the company include installation, training, limited warranties, service agreements, and related support. The company operates in six segments, which include Simulators and Accessories, Extended Service, Customized software and Custom content, Installation and Training, Design and Prototyping, and Subscription Training Equipment Partnership. The majority of its revenue is generated from the Simulators and Accessories segment.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: